x

Coronavirus

AstraZeneca Asks FDA to Authorize COVID Antibody Treatment

LONDON — Officials with drugmaker AstraZeneca have asked the U.S. Food and Drug Administration to authorize the emergency use of an antibody treatment to prevent COVID-19.

The company says the treatment, known as AZD7442, will be the first long-acting antibody combination to receive an emergency use authorization for COVID-19 prevention. AstraZeneca says the drug may help protect people whose immune systems don’t fully respond to vaccination.

U.S. demand for antibody treatments soared over the summer, particularly in Florida, Louisiana and Texas, where hospitalizations among unvaccinated patients threatened to overwhelm the health care system.

The drugs are lab versions of virus-blocking antibodies that help fight off infections. The treatments help the patient by supplying concentrated doses. The main antibody treatment used in the U.S. is Regeneron’s dual-antibody cocktail.

RELATED

NEW YORK (AP) — President Joe Biden promised to distribute hundreds of millions of free COVID-19 tests and to open more testing sites to fight surging infections, but the stepped-up efforts will not come in time for people who want to find out if they are infected before the holidays.

Top Stories

Culture

If you are reading this today, you can thank your parents, grandparents, great-grandparents, and previous ancestors for your existence.

Politics

A former senator, minister, cabinet secretary, chief of staff to Australian former PM John Howard for more than a decade, Arthur Synodinos is Australia’s ambassador to the United States since 2020.

General News

Anton "Tony" Mandros, 87, of Portsmouth, RI, passed to his eternal reward on January 19.

Video

Ouzo Talk Latest Podcast Features My Greek Odyssey’s Peter Maneas

SYDNEY – The latest episode of the Ouzo Talk Podcast for the Greek diaspora is now available, with Peter Maneas, host of the TV series My Greek Odyssey, joining Tom Skolarikis and Nick Athanassiou in the studio to discuss the hit series.

Enter your email address to subscribe

Provide your email address to subscribe. For e.g. abc@xyz.com

You may unsubscribe at any time using the link in our newsletter.